Keryx plunges 87% as Sulonex fails Ph III trial

17 March 2008

USA-based Keryx Biopharmaceuticals has reported disappointing top-line results from its SUN-MICRO trial of Sulonex (sulodexide) for diabetic nephropathy. The company that the Phase III study failed to meet its primary objective, which was to increase the proportion of patients who achieve therapeutic success at six months as compared to placebo over background therapy.

On March 10, the first trading day after the results were announced, shares in Keryx nose-dived 87.3% to an all-time low of $0.67. Michael Weiss, the firm's chief executive, said: "we plan to re-focus our primary efforts and resources on rapidly moving Zerenex forward for end-stage renal disease patients with hyperphosphatemia and Perifosine forward for cancer. Our goal is to have Perifosine in a pivotal program this year and be well into our Zerenex high-dose Phase II trial before the end of the year."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight